Your fact-checks will appear here
The risks of amyloid-related imaging abnormalities, including edema and hemorrhage, associated with lecanemab and donanemab.
Two monoclonal antibodies—lecanemab (Leqembi) and donanemab (Kisunla)—offer modest slowing of early Alzheimer’s symptoms but carry specific, sometimes serious safety risks that require structured moni...
Real‑world reports and pooled analyses show that amyloid‑related imaging abnormalities (ARIA) are substantially more common with anti‑amyloid monoclonal antibodies than with placebo, and that lecanema...
Two monoclonal antibodies—lecanemab and donanemab—have randomized-trial evidence of modest slowing of cognitive decline at 18 months and emerging longer-term data for lecanemab suggesting continued, s...